المؤلفون: Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T, T. Bachelot (France), K. Bouzid (Algeria), M. Campone, I. Desmoulins/B. Coudert (France), I. Bondarenko (Ukraine), Z. Nowecki/I. Glogowska (Poland), E. Ciruelos Gil (Spain), H. Errihani (Morocco), F. Dalenc, F. Ricci/V. Dieras (France), B. Kaufman/S. PaluchShimon (Israel), A. Wardley (UK), A. Schneeweiss (Germany), A. Ferreira (Portugal), M. Mano (Brazil), H. Kalofonos (Greece), C. Andreetta/F. Puglisi, F. Montemurro (Italy), S. Barrett (UK), Q. Zhang (China), D. Mavroudis (Greece), J. Matus/C. Villarreal Garza (Mexico), C. Beato/G. Ismael (Brazil), X. Hu (China), H. Abdel Azeem, R. Gaafar (Egypt), C. Perrin/P. Kerbrat (France), J. Ettl/S. Paepke (Germany), E. Hitre/I. Lang (Hungary), M. Trudeau/S. Verma (Canada), H. Li (China), O. Hoffmann/B. Aktas (Germany), A. Cariello/G. Cruciani/A. Tienghi, C. Tondini (Italy), T. Al-Twegieri (Saudi Arabia), N. Loman (Sweden), R. Laing, D. Miles (UK), E. Brain (France), P. Fasching/M. Lux (Germany), A. Frassoldati (Italy), Z. Aziz (Pakistan), J. Salas (Peru), J. Streb/K. Krzemieniecki, A. Wronski (Poland), J. Garcia Garcia/S. Menjon Beltran (Spain), I. Cicin (Turkey), P. Schmid/C. Gallagher, N. Turner (UK), Z. Tong (China), K. Boer, B. Juhász/Z. Horvath (Hungary), G. Bianchini/L. Gianni, G. Curigliano (Italy), A. Juarez Ramiro (Mexico), S. Susnjar (Serbia), E. Matos (Slovenia), E. Sevillano/L. Garcia Estevez (Spain), E. Gokmen/R. Uslu (Turkey), H. Wildiers (Belgium), F. Schutz/M. Cruz (Brazil), H. Bourgeois (France), R. von Schumann (Germany), S. Stemmer (Israel), A. Dominguez, F. MoralesVásques (Mexico), M. Wojtukiewicz (Poland), J. Trifunovic (Serbia), M. J. Echarri Gonzalez, J. Illarramendi Mañas, E. Martinez De Dueñas (Spain), N. Voitko (Ukraine), J. Hicks, S. Waters/P. Barrett-Lee, D. Wheatley (UK), R. De Boer (Australia), V. Cocquyt, G. Jerusalem (Belgium), C. Barrios (Brazil), L. Panasci (Canada), J. Mattson, M. Tanner (Finland), M. Gozy (France), G. Vasilopoulos/C. Papandreou (Greece), J. Revesz (Hungary), N. Battelli/G. Benedetti/L. Latini, C. Gridelli (Italy), J. Lazaro Leon (Mexico), J. Alarcón Company, A. Arance Fernandez, A. Barnadas Molins, I. Calvo Plaza/R. Bratos/A. Gonzalez Martin, Y. Izarzugaza Peron (Spain), L. Klint (Sweden), A. Kovalev (Ukraine), N. McCarthy, B. Yeo/D. Kee/J. Thomson/S. White (Australia), R. Greil (Austria), S. Wang (China), X. Artignan (France), I. Juhasz-Böess/A. Rody (Germany), R. Ngan (Hong Kong), F. Dourleshter/H. Goldberg (Israel), L. Doni/F. Di Costanzo, F. Ferraù (Italy), M. Drobniene/E. Aleknavicius (Lithuania), K. Rashid (Pakistan), L. Costa (Portugal), L. de la Cruz Merino, J. Garcia Saenz, R. López (Spain), O. Del Val Munoz (Sweden), O. Ozyilkan (Turkey), F. Azribi/H. Jaafar (United Arab Emirates), R. Baird, M. Verrill (UK), J. Beith (Australia), A. Petzer (Austria), J. Moreira de Andrade (Brazil), V. Bernstein/N. Macpherson, D. Rayson (Canada), I. Saad Eldin (Egypt), M. Achille, P. Augereau (France), V. Müller (Germany), A. Rasco/E. Evron/ D. Katz (Israel), R. Berardi/S. Cascinu, A. De Censi, A. Gennari, N. El-Saghir, M. Ghosn (Lebanon), H. M. Oosterkamp, J. Van den Bosch (The Netherlands), M. Kukulska/E. Kalinka (Poland), J. Alonso, E. Dalmau Portulas, M. Del Mar Gordon Santiago, I. Pelaez Fernandez (Spain), S. Aksoy/K. Altundag, H. Senol Coskun/H. Bozcuk (Turkey), Y. Shparyk (Ukraine), L. Barraclough, N. Levitt, U. Panwar/S. Kelly, A. Rigg, M. Varughese (UK), C. Castillo (Uruguay), L. Fein (Argentina), L. Malik/R. Stuart-Harris (Australia), C. Singer, H. Stoeger/H. Samonigg (Austria), J. Feng (China), M. Cedeño (Ecuador), J. Ruohola (Finland), J. -F. Berdah, A. Goncalves, H. Orfeuvre (France), E. -M. Grischke, E. Simon, S. Wagner (Germany), G. Koumakis, K. Papazisis (Greece), N. Ben Baruch, G. Fried, D. Geffen, N. Karminsky, T. Peretz (Israel), L. Cavanna, P. Pedrazzioli/D. Grasso, E. Ruggeri/G. D’Auria/L. Moscetti (Italy), E. Juozaityte (Lithuania), J. Rodriguez Cid (Mexico), H. Roerdink (The Netherlands), N. Siddiqi (Pakistan), J. Passos Coelho (Portugal), A. Arcediano Del Amo, E. Garcia Garre, M. García Gonzalez, A. Garcia-Palomo Perez, C. Herenandez Perez/P. Lopez Alvarez, M. H. Lopez De Ceballos, N. Martínez Jañez, M. Mele Olive (Spain), K. McAdam, T. Perren, G. Dunn, A. Humphreys, W. Taylor (UK), R. Vera (Venezuela), L. Kaen (Argentina), J. Andel, G. Steger (Austria), J. De Grève, M. Huizing (Belgium), R. Hegg (Brazil), A. Joy, P. Kuruvilla/S. Sehdev, S. Smiljanic (Canada), R. Kütner (Estonia), J. Alexandre, J. Grosjean, P. Laplaige, R. Largillier, P. Maes/P. Martin, V. Pottier (France), B. Christensen, F. Khandan, H. -J. Lück, D. -M. Zahm (Germany), C. Papandreou/G. Fountzilas/ V. Karavasilis (Greece), T. Safra/M. Inbar/L. Ryvo (Israel), A. Bonetti, E. Seles/A. Giacobino (Italy), Y. Chavarri Guerra (Mexico), F. de Jongh, A. van der Velden, L. van Warmerdam, S. Vrijaldenhoven/C. H. Smorenburg (The Netherlands), M. Cavero (Peru), R. Andres Conejero, A. Oltra Ferrando, A. Redondo Sanchez, N. Ribelles Entrena, S. Saura Grau, G. Viñas Vilaro (Spain), K. Bachmeier (Sweden), M. Beresford, M. Butt, J. Joffe, C. Poole, P. Woodings/P. Chakraborti (UK), G. Yordi (Venezuela), N. Woodward (Australia), A. Nobre/G. Luiz Amorim (Brazil), N. Califaretti, S. Fox, A. Robidoux (Canada), E. Li, N. Li, J. Jiang (China), T. Soria (Ecuador), P. Padrik (Estonia), O. Lahdenpera (Finland), H. Barletta, N. Dohollou, D. Genet, K. Prulhiere/D. Coeffic/T. Facchini, S. Vieillot/S. Catala, L. Teixeira (France), T. Hesse, T. Kühn, A. Ober, R. Repp, W. Schröder (Germany), D. Pectasides (Greece), G. Bodoky, Z. Kahan (Hungary), I. Jiveliouk, O. Rosengarten (Israel), V. Rossi/O. Alabiso (Italy), M. Pérez Martínez (Mexico), A. J. van de Wouw (The Netherlands), J. Smok-Kalwat/M. Damasecno (Poland), I. Augusto, G. Sousa (Portugal), A. Saadein/N. Abdelhafiez/O. Abulkhair (Saudi Arabia), A. Antón Torres, M. Corbellas Aparicio/R. Llorente Domenech, J. Florián Jerico, J. Garcia Mata, M. Gil Raga/A. Galan Brotons, A. Llombart Cussac, C. Llorca Ferrandiz, P. Martinez Del Prado, C. Olier Garate, C. Rodriguez Sanchez, R. Sanchez Gomez, M. Santisteban Eslava, J. Soberino/M. Vidal Losada Garcia, D. Soto de Prado, J. Torrego Garcia, E. Vicente Rubio/M. Garcia/A. Murias Rosales (Spain), H. Granstam Björneklett, U. Narbe (Sweden), M. Jafri/D. Rea, J. Newby/A. Jones, S. Westwell/A. Ring (UK), I. Alonso, R. Rodríguez (Uruguay).

المساهمون: D, Mile, E, Ciruelo, A, Schneewei, F, Puglisi, T, Peretz-Yablonski, M, Campone, I, Bondarenko, Z, Nowecki, H, Errihani, S, Paluch-Shimon, A, Wardley, Jl, Merot, P, Trask, Y, du Toit, C, Pena-Murillo, V, Revelant, D, Klingbiel, T, Bachelot, Bachelot (France), T., Bouzid (Algeria), K., Campone, M., Coudert (France), I. Desmoulins/B., Bondarenko (Ukraine), I., Glogowska (Poland), Z. Nowecki/I., Ciruelos Gil (Spain), E., Errihani (Morocco), H., Dalenc, F., Dieras (France), F. Ricci/V., PaluchShimon (Israel), B. Kaufman/S., Wardley (UK), A., Schneeweiss (Germany), A., Ferreira (Portugal), A., Mano (Brazil), M., Kalofonos (Greece), H., Puglisi, C. Andreetta/F., Montemurro (Italy), F., Barrett (UK), S., Zhang (China), Q., Mavroudis (Greece), D., Villarreal Garza (Mexico), J. Matus/C., Ismael (Brazil), C. Beato/G., Hu (China), X., Abdel Azeem, H., Gaafar (Egypt), R., Kerbrat (France), C. Perrin/P., Paepke (Germany), J. Ettl/S., Lang (Hungary), E. Hitre/I., Verma (Canada), M. Trudeau/S., Li (China), H., Aktas (Germany), O. Hoffmann/B., Tienghi, A. Cariello/G. Cruciani/A., Tondini (Italy), C., Al-Twegieri (Saudi Arabia), T., Loman (Sweden), N., Laing, R., Miles (UK), D., Brain (France), E., Lux (Germany), P. Fasching/M., Frassoldati (Italy), A., Aziz (Pakistan), Z., Salas (Peru), J., Krzemieniecki, J. Streb/K., Wronski (Poland), A., Menjon Beltran (Spain), J. Garcia Garcia/S., Cicin (Turkey), I., Gallagher, P. Schmid/C., Turner (UK), N., Tong (China), Z., Boer, K., Horvath (Hungary), B. Juhász/Z., Gianni, G. Bianchini/L., Curigliano (Italy), G., Juarez Ramiro (Mexico), A., Susnjar (Serbia), S., Matos (Slovenia), E., Garcia Estevez (Spain), E. Sevillano/L., Uslu (Turkey), E. Gokmen/R., Wildiers (Belgium), H., Cruz (Brazil), F. Schutz/M., Bourgeois (France), H., von Schumann (Germany), R., Stemmer (Israel), S., Dominguez, A., MoralesVásques (Mexico), F., Wojtukiewicz (Poland), M., Trifunovic (Serbia), J., Echarri Gonzalez, M. J., Illarramendi Mañas, J., Martinez De Dueñas (Spain), E., Voitko (Ukraine), N., Hicks, J., Barrett-Lee, S. Waters/P., Wheatley (UK), D., De Boer (Australia), R., Cocquyt, V., Jerusalem (Belgium), G., Barrios (Brazil), C., Panasci (Canada), L., Mattson, J., Tanner (Finland), M.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34224826; info:eu-repo/semantics/altIdentifier/wos/WOS:000709095000007; journal:ANNALS OF ONCOLOGY; http://hdl.handle.net/11579/128409Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85111551739

الإتاحة: https://doi.org/10.1016Test/j.annonc.2021.06.024
http://hdl.handle.net/11579/128409Test

المؤلفون: Casilda Rodríguez, J Garcia-Gomez, C Pernaut, J Garcia-Mata, Nuria Ribelles, Álvaro Rodríguez-Lescure, A Lopez, Joaquín Gavilá, A Urrutikoetxea, Sonia Pernas

المصدر: Cancer Research. 79:P2-13

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, education.field_of_study, business.industry, Population, Cancer, medicine.disease, law.invention, Clinical trial, Breast cancer, Randomized controlled trial, law, Trastuzumab, Internal medicine, Cohort, medicine, Stage (cooking), skin and connective tissue diseases, business, education, medicine.drug

الوصف: INTRODUCTION: Although large randomized trials assessing the benefit of adjuvant trastuzumab in HER2-positive (HER2+) breast cancer have clearly demonstrated a significant improvement in long-term survival, it is necessary to know the impact of the use of trastuzumab adjuvant in the real life population, which includes patients frequently excluded from clinical trials, such as those with very small tumors without node involvement, or advanced age. The objective of this study is to describe the outcomes of women who received adjuvant trastuzumab for HER2+ cáncer since it was approved in 2006, compared with a previous cohort of HER2+ patients not treated with trastuzumab in 7 Spanish centers. METHODS: Women with newly diagnosed stage I-III, HER2+ breast cancer, between 1997 and 2015 were included in the study. Two cohorts were considered: The No-Trastuzumab cohort (No-T), between 1997 and 2005, and the Trastuzumab cohort (T) with trastuzumab-treated women between 2006 and 2015. Kaplan-Meier estimates were used to evaluate DFS and OS. Additionally, cohorts were analyzed by pathologic tumour size, lymph node involvement and hormonal receptor status to stratify outcome measures. RESULTS: A total of 2134 patients were identified. In 164 cases, data were insufficient or the follow-up incomplete. Therefore, the final analysis included 1970 patients, of whom 539 belong to the "No-T" cohort and 1431 to the "T" cohort. The median follow-up was 81 months. Median age: 53 years [22-98]. A total of 699 patients had T1 tumors [43% in the "No-T" cohort vs 33% in the "T" cohort]. 55% of the cases were N0 [58% and 54% in the "No-T" and "T" cohorts respectively]. The status of the hormonal receptors was well balanced between groups [36% ER negative in both]. Regarding the type of adjuvant treatment administered, in the "T" cohort more patients received adjuvant chemotherapy [65% vs 97%] and also in the “T” group combinations of taxanes and anthracyclines were more frequent [14% vs 72%]. The proportion of adjuvant endocrine therapy was similar in both groups [37% vs 34%]. In the “T” cohort, median Disease Free Survival (DFS) was not-reached, compared with 149 months in the “No-T” group. 5-year DFS was 83% vs 65% respectively [p CONCLUSIONS: Adjuvant treatment with Trastuzumab under conditions of real clinical practice in HER2+ early breast cancer, shows a highly significant benefit in terms of DFS and OS, regardless of the stage of the disease or other clinical variables. A very important benefit was reached in patients with small tumors, node-negative disease, or both conditions (T1N0). The benefit was also obtained regardless of the expression of hormonal receptors. Citation Format: Rodriguez CA, Garcia-Gomez J, Ribelles N, Gavila J, Pernas S, Rodriguez-Lescure A, Urrutikoetxea A, Pernaut C, Lopez A, Garcia-Mata J. Impact of the adjuvant treatment with trastuzumab in HER2 positive breast cancer in the real-world setting. Analysis of two cohorts (1997-2005/2006-2015) in 1970 patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-13-04.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::10136e7bc0534d2016f85d4aaf0a8cc4Test
https://doi.org/10.1158/1538-7445.sabcs18-p2-13-04Test

المؤلفون: D. Miles, E. Ciruelos, A. Schneeweiss, F. Puglisi, T. Peretz-Yablonski, M. Campone, I. Bondarenko, Z. Nowecki, H. Errihani, S. Paluch-Shimon, A. Wardley, J.-L. Merot, P. Trask, Y. du Toit, C. Pena-Murillo, V. Revelant, D. Klingbiel, T. Bachelot, K. Bouzid, I. Desmoulins, B. Coudert, I. Glogowska, E. Ciruelos Gil, F. Dalenc, F. Ricci, V. Dieras, B. Kaufman, A. Ferreira, M. Mano, H. Kalofonos, C. Andreetta, F. Montemurro, S. Barrett, Q. Zhang, D. Mavroudis, J. Matus, C. Villarreal Garza, C. Beato, G. Ismael, X. Hu, H. Abdel Azeem, R. Gaafar, C. Perrin, P. Kerbrat, J. Ettl, S. Paepke, E. Hitre, I. Lang, M. Trudeau, S. Verma, H. Li, O. Hoffmann, B. Aktas, A. Cariello, G. Cruciani, A. Tienghi, C. Tondini, T. Al-Twegieri, N. Loman, R. Laing, E. Brain, P. Fasching, M. Lux, A. Frassoldati, Z. Aziz, J. Salas, J. Streb, K. Krzemieniecki, A. Wronski, J. Garcia Garcia, S. Menjon Beltran, I. Cicin, P. Schmid, C. Gallagher, N. Turner, Z. Tong, K. Boer, B. Juhász, Z. Horvath, G. Bianchini, L. Gianni, G. Curigliano, A. Juarez Ramiro, S. Susnjar, E. Matos, E. Sevillano, L. Garcia Estevez, E. Gokmen, R. Uslu, H. Wildiers, F. Schutz, M. Cruz, H. Bourgeois, R. von Schumann, S. Stemmer, A. Dominguez, F. Morales-Vásques, M. Wojtukiewicz, J. Trifunovic, M.J. Echarri Gonzalez, J. Illarramendi Mañas, E. Martinez De Dueñas, N. Voitko, J. Hicks, S. Waters, P. Barrett-Lee, D. Wheatley, R. De Boer, V. Cocquyt, G. Jerusalem, C. Barrios, L. Panasci, J. Mattson, M. Tanner, M. Gozy, G. Vasilopoulos, C. Papandreou, J. Revesz, N. Battelli, G. Benedetti, L. Latini, C. Gridelli, J. Lazaro Leon, J. Alarcón Company, A. Arance Fernandez, A. Barnadas Molins, I. Calvo Plaza, R. Bratos, A. Gonzalez Martin, Y. Izarzugaza Peron, L. Klint, A. Kovalev, N. McCarthy, B. Yeo, D. Kee, J. Thomson, S. White, R. Greil, S. Wang, X. Artignan, I. Juhasz-Böess, A. Rody, R. Ngan, F. Dourleshter, H. Goldberg, L. Doni, F. Di Costanzo, F. Ferraù, M. Drobniene, E. Aleknavicius, K. Rashid, L. Costa, L. de la Cruz Merino, J. Garcia Saenz, R. López, O. Del Val Munoz, O. Ozyilkan, F. Azribi, H. Jaafar, R. Baird, M. Verrill, J. Beith, A. Petzer, J. Moreira de Andrade, V. Bernstein, N. Macpherson, D. Rayson, I. Saad Eldin, M. Achille, P. Augereau, V. Müller, A. Rasco, E. Evron, D. Katz, R. Berardi, S. Cascinu, A. De Censi, A. Gennari, N. El-Saghir, M. Ghosn, H.M. Oosterkamp, J. Van den Bosch, M. Kukulska, E. Kalinka, J. Alonso, E. Dalmau Portulas, M. Del Mar Gordon Santiago, I. Pelaez Fernandez, S. Aksoy, K. Altundag, H. Senol Coskun, H. Bozcuk, Y. Shparyk, L. Barraclough, N. Levitt, U. Panwar, S. Kelly, A. Rigg, M. Varughese, C. Castillo, L. Fein, L. Malik, R. Stuart-Harris, C. Singer, H. Stoeger, H. Samonigg, J. Feng, M. Cedeño, J. Ruohola, J.-F. Berdah, A. Goncalves, H. Orfeuvre, E.-M. Grischke, E. Simon, S. Wagner, G. Koumakis, K. Papazisis, N. Ben Baruch, G. Fried, D. Geffen, N. Karminsky, T. Peretz, L. Cavanna, P. Pedrazzioli, D. Grasso, E. Ruggeri, G. D’Auria, L. Moscetti, E. Juozaityte, J. Rodriguez Cid, H. Roerdink, N. Siddiqi, J. Passos Coelho, A. Arcediano Del Amo, E. Garcia Garre, M. García Gonzalez, A. Garcia-Palomo Perez, C. Herenandez Perez, P. Lopez Alvarez, M.H. Lopez De Ceballos, N. Martínez Jañez, M. Mele Olive, K. McAdam, T. Perren, G. Dunn, A. Humphreys, W. Taylor, R. Vera, L. Kaen, J. Andel, G. Steger, J. De Grève, M. Huizing, R. Hegg, A. Joy, P. Kuruvilla, S. Sehdev, S. Smiljanic, R. Kütner, J. Alexandre, J. Grosjean, P. Laplaige, R. Largillier, P. Maes, P. Martin, V. Pottier, B. Christensen, F. Khandan, H.-J. Lück, D.-M. Zahm, G. Fountzilas, V. Karavasilis, T. Safra, M. Inbar, L. Ryvo, A. Bonetti, E. Seles, A. Giacobino, Y. Chavarri Guerra, F. de Jongh, A. van der Velden, L. van Warmerdam, S. Vrijaldenhoven, C.H. Smorenburg, M. Cavero, R. Andres Conejero, A. Oltra Ferrando, A. Redondo Sanchez, N. Ribelles Entrena, S. Saura Grau, G. Viñas Vilaro, K. Bachmeier, M. Beresford, M. Butt, J. Joffe, C. Poole, P. Woodings, P. Chakraborti, G. Yordi, N. Woodward, A. Nobre, G. Luiz Amorim, N. Califaretti, S. Fox, A. Robidoux, E. Li, N. Li, J. Jiang, T. Soria, P. Padrik, O. Lahdenpera, H. Barletta, N. Dohollou, D. Genet, K. Prulhiere, D. Coeffic, T. Facchini, S. Vieillot, S. Catala, L. Teixeira, T. Hesse, T. Kühn, A. Ober, R. Repp, W. Schröder, D. Pectasides, G. Bodoky, Z. Kahan, I. Jiveliouk, O. Rosengarten, V. Rossi, O. Alabiso, M. Pérez Martínez, A.J. van de Wouw, J. Smok-Kalwat, M. Damasecno, I. Augusto, G. Sousa, A. Saadein, N. Abdelhafiez, O. Abulkhair, A. Antón Torres, M. Corbellas Aparicio, R. Llorente Domenech, J. Florián Jerico, J. Garcia Mata, M. Gil Raga, A. Galan Brotons, A. Llombart Cussac, C. Llorca Ferrandiz, P. Martinez Del Prado, C. Olier Garate, C. Rodriguez Sanchez, R. Sanchez Gomez, M. Santisteban Eslava, J. Soberino, M. Vidal Losada Garcia, D. Soto de Prado, J. Torrego Garcia, E. Vicente Rubio, M. Garcia, A. Murias Rosales, H. Granstam Björneklett, U. Narbe, M. Jafri, D. Rea, J. Newby, A. Jones, S. Westwell, A. Ring, I. Alonso, R. Rodríguez

المساهمون: Miles, D., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Campone, M., Bondarenko, I., Nowecki, Z., Errihani, H., Paluch-Shimon, S., Wardley, A., Merot, J. -L., Trask, P., du Toit, Y., Pena-Murillo, C., Revelant, V., Klingbiel, D., Bachelot, T., Bouzid, K., Desmoulins, I., Coudert, B., Glogowska, I., Ciruelos Gil, E., Dalenc, F., Ricci, F., Dieras, V., Kaufman, B., Ferreira, A., Mano, M., Kalofonos, H., Andreetta, C., Montemurro, F., Barrett, S., Zhang, Q., Mavroudis, D., Matus, J., Villarreal Garza, C., Beato, C., Ismael, G., Hu, X., Abdel Azeem, H., Gaafar, R., Perrin, C., Kerbrat, P., Ettl, J., Paepke, S., Hitre, E., Lang, I., Trudeau, M., Verma, S., Li, H., Hoffmann, O., Aktas, B., Cariello, A., Cruciani, G., Tienghi, A., Tondini, C., Al-Twegieri, T., Loman, N., Laing, R., Brain, E., Fasching, P., Lux, M., Frassoldati, A., Aziz, Z., Salas, J., Streb, J., Krzemieniecki, K., Wronski, A., Garcia Garcia, J., Menjon Beltran, S., Cicin, I., Schmid, P., Gallagher, C., Turner, N., Tong, Z., Boer, K., Juhasz, B., Horvath, Z., Bianchini, G., Gianni, L., Curigliano, G., Juarez Ramiro, A., Susnjar, S., Matos, E., Sevillano, E., Garcia Estevez, L., Gokmen, E., Uslu, R., Wildiers, H., Schutz, F., Cruz, M., Bourgeois, H., von Schumann, R., Stemmer, S., Dominguez, A., Morales-Vasques, F., Wojtukiewicz, M., Trifunovic, J., Echarri Gonzalez, M. J., Illarramendi Manas, J., Martinez De Duenas, E., Voitko, N., Hicks, J., Waters, S., Barrett-Lee, P., Wheatley, D., De Boer, R., Cocquyt, V., Jerusalem, G., Barrios, C., Panasci, L., Mattson, J., Tanner, M., Gozy, M., Vasilopoulos, G., Papandreou, C., Revesz, J., Battelli, N., Benedetti, G., Latini, L., Gridelli, C., Lazaro Leon, J., Alarcon Company, J., Arance Fernandez, A., Barnadas Molins, A., Calvo Plaza, I., Bratos, R., Gonzalez Martin, A., Izarzugaza Peron, Y., Klint, L., Kovalev, A., Mccarthy, N., Yeo, B., Kee, D., Thomson, J., White, S., Greil, R., Wang, S., Artignan, X., Juhasz-Boess, I., Rody, A., Ngan, R., Dourleshter, F., Goldberg, H., Doni, L., Di Costanzo, F., Ferrau, F., Drobniene, M., Aleknavicius, E., Rashid, K., Costa, L., de la Cruz Merino, L., Garcia Saenz, J., Lopez, R., Del Val Munoz, O., Ozyilkan, O., Azribi, F., Jaafar, H., Baird, R., Verrill, M., Beith, J., Petzer, A., Moreira de Andrade, J., Bernstein, V., Macpherson, N., Rayson, D., Saad Eldin, I., Achille, M., Augereau, P., Muller, V., Rasco, A., Evron, E., Katz, D., Berardi, R., Cascinu, S., De Censi, A., Gennari, A., El-Saghir, N., Ghosn, M., Oosterkamp, H. M., Van den Bosch, J., Kukulska, M., Kalinka, E., Alonso, J., Dalmau Portulas, E., Del Mar Gordon Santiago, M., Pelaez Fernandez, I., Aksoy, S., Altundag, K., Senol Coskun, H., Bozcuk, H., Shparyk, Y., Barraclough, L., Levitt, N., Panwar, U., Kelly, S., Rigg, A., Varughese, M., Castillo, C., Fein, L., Malik, L., Stuart-Harris, R., Singer, C., Stoeger, H., Samonigg, H., Feng, J., Cedeno, M., Ruohola, J., Berdah, J. -F., Goncalves, A., Orfeuvre, H., Grischke, E. -M., Simon, E., Wagner, S., Koumakis, G., Papazisis, K., Ben Baruch, N., Fried, G., Geffen, D., Karminsky, N., Peretz, T., Cavanna, L., Pedrazzioli, P., Grasso, D., Ruggeri, E., D'Auria, G., Moscetti, L., Juozaityte, E., Rodriguez Cid, J., Roerdink, H., Siddiqi, N., Passos Coelho, J., Arcediano Del Amo, A., Garcia Garre, E., Garcia Gonzalez, M., Garcia-Palomo Perez, A., Herenandez Perez, C., Lopez Alvarez, P., Lopez De Ceballos, M. H., Martinez Janez, N., Mele Olive, M., Mcadam, K., Perren, T., Dunn, G., Humphreys, A., Taylor, W., Vera, R., Kaen, L., Andel, J., Steger, G., De Greve, J., Huizing, M., Hegg, R., Joy, A., Kuruvilla, P., Sehdev, S., Smiljanic, S., Kutner, R., Alexandre, J., Grosjean, J., Laplaige, P., Largillier, R., Maes, P., Martin, P., Pottier, V., Christensen, B., Khandan, F., Luck, H. -J., Zahm, D. -M., Fountzilas, G., Karavasilis, V., Safra, T., Inbar, M., Ryvo, L., Bonetti, A., Seles, E., Giacobino, A., Chavarri Guerra, Y., de Jongh, F., van der Velden, A., van Warmerdam, L., Vrijaldenhoven, S., Smorenburg, C. H., Cavero, M., Andres Conejero, R., Oltra Ferrando, A., Redondo Sanchez, A., Ribelles Entrena, N., Saura Grau, S., Vinas Vilaro, G., Bachmeier, K., Beresford, M., Butt, M., Joffe, J., Poole, C., Woodings, P., Chakraborti, P., Yordi, G., Woodward, N., Nobre, A., Luiz Amorim, G., Califaretti, N., Fox, S., Robidoux, A., Li, E., Li, N., Jiang, J., Soria, T., Padrik, P., Lahdenpera, O., Barletta, H., Dohollou, N., Genet, D., Prulhiere, K., Coeffic, D., Facchini, T., Vieillot, S., Catala, S., Teixeira, L., Hesse, T., Kuhn, T., Ober, A., Repp, R., Schroder, W., Pectasides, D., Bodoky, G., Kahan, Z., Jiveliouk, I., Rosengarten, O., Rossi, V., Alabiso, O., Perez Martinez, M., van de Wouw, A. J., Smok-Kalwat, J., Damasecno, M., Augusto, I., Sousa, G., Saadein, A., Abdelhafiez, N., Abulkhair, O., Anton Torres, A., Corbellas Aparicio, M., Llorente Domenech, R., Florian Jerico, J., Garcia Mata, J., Gil Raga, M., Galan Brotons, A., Llombart Cussac, A., Llorca Ferrandiz, C., Martinez Del Prado, P., Olier Garate, C., Rodriguez Sanchez, C., Sanchez Gomez, R., Santisteban Eslava, M., Soberino, J., Vidal Losada Garcia, M., Soto de Prado, D., Torrego Garcia, J., Vicente Rubio, E., Garcia, M., Murias Rosales, A., Granstam Bjorneklett, H., Narbe, U., Jafri, M., Rea, D., Newby, J., Jones, A., Westwell, S., Ring, A., Alonso, I., Rodriguez, R., Apollo - University of Cambridge Repository, Medical Genetics, Clinical sciences, Laboratory for Medical and Molecular Oncology

مصطلحات موضوعية: 0301 basic medicine, Oncology, Receptor, ErbB-2, medicine.medical_treatment, chemistry.chemical_compound, paclitaxel, 0302 clinical medicine, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, skin and connective tissue diseases, HER2 positive, hormone receptor, metastatic breast cancer, overall survival, pertuzumab, Hematology, Metastatic breast cancer, Receptor, ErbB-2/genetics, Neoplasm Recurrence, Local/drug therapy, Treatment Outcome, Docetaxel, Paclitaxel, 030220 oncology & carcinogenesis, Female, Taxoids, Pertuzumab, medicine.drug, medicine.medical_specialty, Taxoids/therapeutic use, Breast Neoplasms, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Breast Neoplasms/drug therapy, Internal medicine, medicine, Humans, Trastuzumab/adverse effects, neoplasms, Chemotherapy, Taxane, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, medicine.disease, 030104 developmental biology, chemistry, Neoplasm Recurrence, Local, business

الوصف: Background The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive locally recurrent/metastatic breast cancer (LR/mBC). The multicentre single-arm PERtUzumab global SafEty (PERUSE) study assessed the safety and efficacy of pertuzumab and trastuzumab combined with investigator-selected taxane in this setting. Patients and methods Eligible patients with inoperable HER2-positive LR/mBC and no prior systemic therapy for LR/mBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab and pertuzumab until disease progression or unacceptable toxicity. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Prespecified subgroup analyses included subgroups according to taxane, hormone receptor (HR) status and prior trastuzumab. Exploratory univariable analyses identified potential prognostic factors; those that remained significant in multivariable analysis were used to analyse PFS and OS in subgroups with all, some or none of these factors. Results Of 1436 treated patients, 588 (41%) initially received paclitaxel and 918 (64%) had HR-positive disease. The most common grade ≥3 adverse events were neutropenia (10%, mainly with docetaxel) and diarrhoea (8%). At the final analysis (median follow-up: 5.7 years), median PFS was 20.7 [95% confidence interval (CI) 18.9-23.1] months overall and was similar irrespective of HR status or taxane. Median OS was 65.3 (95% CI 60.9-70.9) months overall. OS was similar regardless of taxane backbone but was more favourable in patients with HR-positive than HR-negative LR/mBC. In exploratory analyses, trastuzumab-pretreated patients with visceral disease had the shortest median PFS (13.1 months) and OS (46.3 months). Conclusions Mature results from PERUSE show a safety and efficacy profile consistent with results from CLEOPATRA and median OS exceeding 5 years. Results suggest that paclitaxel is a valid alternative to docetaxel as backbone chemotherapy. Exploratory analyses suggest risk factors that could guide future trial design.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5b0239f57f26e8e989f5c39d68eb580Test
http://hdl.handle.net/11390/1209378Test

المؤلفون: J. Cubiella, M. Salgado, M. Riú, J. García-Mata, E. Sánchez, M. S. Díez, R. Rodríguez, M. Vega

المصدر: Revista Espanola de Enfermedades Digestivas, Vol 96, Iss 2, Pp 150-151 (2004)

مصطلحات موضوعية: Diseases of the digestive system. Gastroenterology, RC799-869

العلاقة: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082004000200011Test; https://doaj.org/toc/1130-0108Test; https://doaj.org/article/488bf73dd57a4ef88dbc087c4afd8becTest

الإتاحة: https://doaj.org/article/488bf73dd57a4ef88dbc087c4afd8becTest

المؤلفون: J. Garcia-Mata, M. Arias, M. Penin, T. Garcia-Caballero, M. E. Pérez-López

المصدر: The Breast. 24:S40

مصطلحات موضوعية: Oncology, Prognostic variable, medicine.medical_specialty, business.industry, General Medicine, medicine.disease, Exact test, Breast cancer, Internal medicine, Adjuvant therapy, Medicine, Immunohistochemistry, Population study, Surgery, business, Grading (tumors), Triple-negative breast cancer

الوصف: Goals: To determine differences in TNBC between expression of cytokeratins 5 and 6 (CK 5/6) and their prognosis. Methods: Data from 888 consecutive female patients with invasive breast cancer but without metastatic disease, who had undergone surgery and were registered between 1 January 1997 and 31 December 2004 in the Tumour Registry of the University Hospital of Ourense (CHUO), Galicia, Spain, were collated and analysed. 100 of them were triple negative breast cancer. IHC was then performed on archived biopsies from the patients, who were thus classified by breast cancer subtype. First, a descriptive analysis of the study population was performed. Qualitative variables were analysed as absolute percentages and relative frequencies, and quantitative variables in terms of central tendency values, i.e. mean. Statistical analyses were then performed, using statistical tests appropriate to each type of variable, i.e. Chi-square test or Fisher’s exact test. Global survival and disease-free survival, using Cox regressions and Kaplan–Meier estimates, were calculated for classical prognostic variables (included age, tumour size and grade, node involvement). We present the results of triple negative breast cancer cases, which were divided in “basal like” and “no basal like” by CK 5/6 expression. SPSS version 17.0 (SPSS Inc., Chicago, IL) was used for all statistical analyses. Results were considered significant when p < 0.05. Results: One hundred triple negative (11.26%) cases among a total of 888 breast cancers were identified: 48 basal like (48%), 45 (45%) no basal like and 7 of them unclassified, because it was not possible to find histological samples. The basal like subtype showed CK 5/6 expression and no basal like absence of this expression. The relapse happened in 28% of TNBC. 42% of the relapses were visceral metastasis, 10% in nervous central system (CNS) and 7% in bones. There was more recurrences in CNS in basal-like than no basal like subtype (11 versus 7%) There was much more mortality-related breast cancer in basal like than in patients with the no basal like subtype (23% versus 18%) and much higher non-cancer-related mortality in patients with no basal like subtype. Patients without node involvement (N0) and basal like subtype had more relapses than no basal like subtype (22 versus 12.5%). None of the no basal like subtype patients died. Nevertheless, 22% of patients of basal like subtype died. Conclusion: TNBC is a bad prognostic factor in multivariate analyses, independent of size, nodal involvement and grading. By immunohistochemical expression of CK 5/6 we classified TNBC in basal like and no basal like subtypes, founded prognostic differences. Even though patients with no basal like tumors relapse, it seems that they have a lesser aggressive behavior. In contrast, basal like subtype tumors have a threatening prognosis with a short time between relapse and death. This evidence must make us think about the consideration of more intense adjuvant therapy in basal like TNBC to decrease relapse and death. Disclosure of Interest: No significant relationships.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::12e23d519d920fb814ff82397eddb1bdTest
https://doi.org/10.1016/s0960-9776Test(15)70089-5